Safety, tolerability and pharmacodynamics of a novel immunomodulator, MIS416, in patients with chronic progressive multiple sclerosis
Background Preclinical studies have demonstrated that MIS416, a bacterially derived immune modulator, targets myeloid cells following systemic delivery. MIS416 stimulated myeloid cells have the capacity to regulate innate inflammation, a potential therapeutic target for progressive multiple sclerosi...
Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
SAGE Publishing
2015-05-01
|
| Collection: | Multiple Sclerosis Journal - Experimental, Translational and Clinical |
| Accès en ligne: | https://doi.org/10.1177/2055217315583385 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|